title: Allogeneic bone marrow transplantation for leukemia following piperazinedione and fractionated total body irradiation.
abstract: Between 1980 and 1988, 126 patients with leukemia were treated with piperazinedione and fractionated total body irradiation (TBI) followed by allogeneic bone marrow transplantation from HLA matched siblings. Sixty-one patients had acute myelogenous leukemia, 46 acute lymphoblastic leukemia, and 19 chronic myelogenous leukemia. Patients with acute leukemia in first complete remission were transplanted only if perceived to have a low probability of remaining in remission with conventional therapy. The toxicity from the preparative regimen was similar to that of cyclophosphamide and TBI except that none of the patients in the study had hemorrhagic cystitis or veno-occlusive disease. After a median follow up of 114 months, 29 patients (23%) are still alive without relapse. The survival of patients with acute myelogenous or lymphoblastic leukemia transplanted in their first remission were 35% and 43%, respectively. The survival of patients transplanted in their first chronic phase of chronic myelogenous leukemia was 60%. The results of this preparative regimen are comparable to those of cyclophosphamide and TBI.
authors.affiliation: University of Texas M.D. Anderson Cancer Center, Houston.
authors.forename: M A
authors.initials: MA
authors.lastname: Dimopoulos
authors.forename: J C
authors.initials: JC
authors.lastname: Yau
authors.forename: S D
authors.initials: SD
authors.lastname: Huan
authors.forename: S
authors.initials: S
authors.lastname: Jagannath
authors.forename: G
authors.initials: G
authors.lastname: Spitzer
authors.forename: J A
authors.initials: JA
authors.lastname: Spinolo
authors.forename: G K
authors.initials: GK
authors.lastname: Zagars
authors.forename: C F
authors.initials: CF
authors.lastname: LeMaistre
authors.forename: K A
authors.initials: KA
authors.lastname: Dicke
authors.forename: A R
authors.initials: AR
authors.lastname: Zander
mesh_terms: D000293:Adolescent; D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000379:methods*; D002648:Child; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy*; D016019:Survival Analysis; D014916:Whole-Body Irradiation
chemical_list: D000903:Antibiotics, Antineoplastic; D010879:Piperazines; C003905:3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione